|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������,�������� |
|
���� |
| ��������������� | |
|
���㷼 |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
������������������Ƶ��о���չ
���㷼, ��ά��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
��������������������举Ů��������ֳ����Ⱦ�Լ���,���е������ֶΰ����ֲ���ϵͳ��ҩ,�Է�ֹ�������þ�����,�µĿ����ҩ��Ŀ�������������Ϊ�������������������������������ϣ����
[2] Upmalis DH, Cone FL, Lamia CA, et al. Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis:two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days. J Womens Health Gend Based Med, 2000, 9:421-429.
[3] Dellenbach P, Thomas JL, Guerin V, et al. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int J Gynaecol Obstet, 2000, 71:S47-52.
[4] Quereux C, Gelas B, Chevallier T, et al. Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil, 2000, 28:238-244.
[5] Brown D, Henzl MR, Kaufman RH. Butoconazole nitrate.2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs.seven-day treatment with miconazole nitrate. Gynasole 1 Study Group.J Reprod Med, 1999, 44:933-938.
[6] del Palacio A, Sanz F, Sanchez-Alor G, et al. Double-blind randomized dose-finding study in acute vulvovaginal candidosis. Comparison of flutrimazole site-release cream (1,2 and 4%) with placebo site-release vaginal cream. Mycoses, 2000, 43:355-365.
[7] No authors listed. Management of genital candidiasis. Working Group of the British Society for Medical Mycology. BMJ, 1995, 310:1241-1244.
[8] Kubota T. Chronic and recurrent vulvovaginal candidiasis. Nippon Ishinkin Gakkai Zasshi, 1998, 39:213-218.
[9] Guasehino S, De Seta F, Sartore A, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconasole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol, 2001, 184:598-602.
[10] White DJ, Habib AR, Vanthuyne A, et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect, 2001, 77:212-213.
[11] Stevens DA, Calderon L, Martinez M, et al. Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. J Antimicrob Chemother, 2002, 50:36l-364.
[12] Karag'ozov I, Shopova E, Poriazov K, et al. A multicenter study of the antimicrobial effect of Macmiror and Macmiror Complex in the treatment of vaginal infections. Akush Ginekol (Sofiia), 1999, 38:61-62.
[13] Ozyurt E, Toykuliyeva MB, Danilyans IL, et al. Efficacy of 7-day treatment with metronidazole + miconazole (Neo-Penotran)-a tripleactive pessary for the treatment of single and mixed vaginal infections.Int J Gynaecol Obstet, 2001,74:35-43.
[14] Spinillo A, Colonna L, Piazzi G, et al. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. J Reprod Med, 1997, 42:83-87.
[15] Martinez A, Ferrer S, Santos 1, et al. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. Antimicrob Agents Chemother, 2001,45:3304-3309.
[16] Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother,2001,45:3433-3436.
[17] Petraitis V, Petraitiene R, Groll AH, et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother, 2001,45:471-479.
[18] Lass-Florl C, Dierich MP, Fuchs D,et al. Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis, 2001,33:E135-136.
[19] Altamura M, Casale D, Pepe M,et al. Immune responses to fungal infections and therapeutic implications. Curt Drug Targets Immune Endocr Metabol Disord, 2001, 1:189-197.
[20] De Bernardis F, Boccanera M, Adriani D, et al. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun, 2002, 70:2725-2729.